Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma
| Autor: | Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Performance status business.industry medicine.medical_treatment Retrospective cohort study Odds ratio 030230 surgery medicine.disease Confidence interval 03 medical and health sciences Regimen 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Internal medicine Diabetes mellitus medicine Adenocarcinoma Surgery business Neoadjuvant therapy |
| Zdroj: | Annals of Surgical Oncology. 27:2961-2971 |
| ISSN: | 1534-4681 1068-9265 |
| Popis: | Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify predictors of disease progression or performance status decline during NT. Retrospective cohort analysis of consecutive patients with localized head-PDC who received NT at a tertiary referral center between 2005 and 2017. Univariate and multivariate (MVA) analysis were performed to identify factors associated with disease progression or performance status decline during NT preventing surgical resection. A total of 479 patients with PDC underwent NT; 71.2% proceeded to surgery, 20.5% had disease progression, and 8.3% experienced performance status decline. Median OS was 28 [95% confidence interval (CI) 23.8–32.3], 12.8 (CI 11.2–14.3), and 6.9 (CI 5.2–9.4) months, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink